| pubmed-article:17940975 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17940975 | lifeskim:mentions | umls-concept:C0282687 | lld:lifeskim |
| pubmed-article:17940975 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17940975 | lifeskim:mentions | umls-concept:C1170000 | lld:lifeskim |
| pubmed-article:17940975 | pubmed:dateCreated | 2007-10-17 | lld:pubmed |
| pubmed-article:17940975 | pubmed:abstractText | Infection of primates with Zaire ebolavirus (ZEBOV) leads to hypotension, coagulation disorders, and an impaired immune response and, in many ways, resembles severe sepsis. Rapid decreases in plasma levels of protein C are a prominent feature of severe sepsis and ZEBOV hemorrhagic fever (ZHF). Currently, recombinant human activated protein C (rhAPC [Xigris; Eli Lilly]) is licensed for treating human patients with severe sepsis who are at high risk of death. The aim of this study was to test the efficacy of rhAPC as a potential treatment for ZHF. | lld:pubmed |
| pubmed-article:17940975 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17940975 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17940975 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:17940975 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17940975 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17940975 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17940975 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17940975 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17940975 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:17940975 | pubmed:issn | 0022-1899 | lld:pubmed |
| pubmed-article:17940975 | pubmed:author | pubmed-author:HensleyLisa... | lld:pubmed |
| pubmed-article:17940975 | pubmed:author | pubmed-author:JahrlingPeter... | lld:pubmed |
| pubmed-article:17940975 | pubmed:author | pubmed-author:GeisbertThoma... | lld:pubmed |
| pubmed-article:17940975 | pubmed:author | pubmed-author:GeisbertJoan... | lld:pubmed |
| pubmed-article:17940975 | pubmed:author | pubmed-author:CassellGail... | lld:pubmed |
| pubmed-article:17940975 | pubmed:author | pubmed-author:YanS BettySB | lld:pubmed |
| pubmed-article:17940975 | pubmed:author | pubmed-author:MaciasWilliam... | lld:pubmed |
| pubmed-article:17940975 | pubmed:author | pubmed-author:LarsenTomT | lld:pubmed |
| pubmed-article:17940975 | pubmed:author | pubmed-author:Daddario-DiCa... | lld:pubmed |
| pubmed-article:17940975 | pubmed:author | pubmed-author:StevensEdward... | lld:pubmed |
| pubmed-article:17940975 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17940975 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:17940975 | pubmed:volume | 196 Suppl 2 | lld:pubmed |
| pubmed-article:17940975 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17940975 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17940975 | pubmed:pagination | S390-9 | lld:pubmed |
| pubmed-article:17940975 | pubmed:meshHeading | pubmed-meshheading:17940975... | lld:pubmed |
| pubmed-article:17940975 | pubmed:meshHeading | pubmed-meshheading:17940975... | lld:pubmed |
| pubmed-article:17940975 | pubmed:meshHeading | pubmed-meshheading:17940975... | lld:pubmed |
| pubmed-article:17940975 | pubmed:meshHeading | pubmed-meshheading:17940975... | lld:pubmed |
| pubmed-article:17940975 | pubmed:meshHeading | pubmed-meshheading:17940975... | lld:pubmed |
| pubmed-article:17940975 | pubmed:meshHeading | pubmed-meshheading:17940975... | lld:pubmed |
| pubmed-article:17940975 | pubmed:meshHeading | pubmed-meshheading:17940975... | lld:pubmed |
| pubmed-article:17940975 | pubmed:meshHeading | pubmed-meshheading:17940975... | lld:pubmed |
| pubmed-article:17940975 | pubmed:meshHeading | pubmed-meshheading:17940975... | lld:pubmed |
| pubmed-article:17940975 | pubmed:meshHeading | pubmed-meshheading:17940975... | lld:pubmed |
| pubmed-article:17940975 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17940975 | pubmed:articleTitle | Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. | lld:pubmed |
| pubmed-article:17940975 | pubmed:affiliation | Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA. | lld:pubmed |
| pubmed-article:17940975 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17940975 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:17940975 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17940975 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17940975 | lld:pubmed |
